High Revenue Growth Stocks in Health Care
Companies with year-over-year revenue growth exceeding 10%, indicating meaningful business expansion.
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
91 Companies Meeting Criteria
Showing 51–91 of 91 companies, ranked by Revenue Growth.
| # | Company | Revenue Growth | Revenue |
|---|---|---|---|
| 51 | LLYLilly (Eli) | 44.7% | $59.4B |
| 52 | ANIPANI Pharmaceuticals, Inc. | 43.8% | $614M |
| 53 | XERSXeris Biopharma Holdings, Inc. | 43.7% | $203M |
| 54 | ONCBeOne Medicines Ltd. | 40.2% | $3.8B |
| 55 | ZYMEZymeworks Inc. | 38.9% | $134M |
| 56 | HALOHalozyme | 37.6% | $1.2B |
| 57 | HROWHARROW, INC. | 36.4% | $200M |
| 58 | DBVTDBV Technologies S.A. | 35.8% | $4M |
| 59 | KRYSKrystal Biotech, Inc. | 33.9% | $291M |
| 60 | IMCRImmunocore Holdings plc | 29.0% | $310M |
| 61 | APLSApellis Pharmaceuticals, Inc. | 28.5% | $781M |
| 62 | PAHCPhibro Animal Health | 27.4% | $1.3B |
| 63 | RXRXRECURSION PHARMACEUTICALS, INC. | 26.9% | $59M |
| 64 | KURAKura Oncology, Inc. | 25.2% | $54M |
| 65 | CRONCronos Group Inc. | 24.6% | $118M |
| 66 | COLLCollegium Pharmaceutical, Inc. | 23.6% | $631M |
| 67 | MNKDMANNKIND CORP | 22.2% | $286M |
| 68 | ARDXARDELYX, INC. | 22.1% | $334M |
| 69 | HRMYHarmony Biosciences Holdings, Inc. | 21.5% | $715M |
| 70 | NBIXNeurocrine Biosciences | 21.4% | $2.7B |
| 71 | ESPREsperion Therapeutics, Inc. | 21.3% | $332M |
| 72 | INCYIncyte | 21.2% | $4.8B |
| 73 | DAWNDay One Biopharmaceuticals, Inc. | 20.6% | - |
| 74 | AUPHAurinia Pharmaceuticals Inc. | 20.4% | $235M |
| 75 | RAREUltragenyx Pharmaceutical Inc. | 20.2% | $631M |
| 76 | FOLDAMICUS THERAPEUTICS, INC. | 20.0% | $528M |
| 77 | UPBUpstream Bio, Inc. | 19.9% | $2M |
| 78 | CPRXCatalyst Pharmaceuticals Partners, Inc. | 19.8% | $492M |
| 79 | ADMAADMA Biologics, Inc. | 19.6% | $426M |
| 80 | DVAXDynavax Technologies Corp. | 19.4% | $277M |
| 81 | VCELVericel | 16.5% | $259M |
| 82 | SRPTSarepta Therapeutics | 15.6% | $2.4B |
| 83 | ZLABZai Lab Ltd | 15.3% | $399M |
| 84 | INVAInnoviva, Inc. | 14.7% | $359M |
| 85 | XNCRXencor Inc | 13.7% | $110M |
| 86 | BMRNBioMarin Pharmaceutical | 12.9% | $3.1B |
| 87 | CORTCorcept Therapeutics Incorporated | 12.8% | $675M |
| 88 | ROIVRoivant Sciences | 12.6% | $29M |
| 89 | ACADAcadia Pharmaceuticals | 11.9% | $1.0B |
| 90 | UTHRUnited Therapeutics | 10.6% | $3.1B |
| 91 | GYREGYRE THERAPEUTICS, INC. | 10.2% | $106M |
Understanding Revenue Growth
Revenue growth above 10% is considered strong for large-cap companies. It typically signals increasing demand, successful new products, or geographic expansion. Growth rates are calculated from the two most recent annual SEC filings. One-time events like acquisitions can inflate growth temporarily.
YoY Revenue Growth > 10%
Results are based on SEC EDGAR filings. Companies with missing, unreliable, or extreme outlier values are excluded from screening.
Related Rankings
See the top companies ranked by these related metrics